Silence Therapeutics バランスシートの健全性

財務の健全性基準チェック /66

Silence Therapeuticsの総株主資本は£112.5M 、総負債は£0.0で、負債比率は0%となります。総資産と総負債はそれぞれ£188.6Mと£76.1Mです。

主要情報

負債資本比率

UK£0

負債

インタレスト・カバレッジ・レシオ	n/a
現金	UK£149.59m
エクイティ	UK£112.51m
負債合計	UK£76.13m
総資産	UK£188.64m

財務の健全性に関する最新情報

Recent updates

財務状況分析

短期負債: SLNC.Fの短期資産 ( £176.4M ) が短期負債 ( £17.9M ) を超えています。

長期負債: SLNC.Fの短期資産 ( £176.4M ) が長期負債 ( £58.2M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: SLNC.Fは負債がありません。

負債の削減: SLNC.F 5 年前には負債がありませんでした。

貸借対照表

キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: SLNC.Fは、現在のフリーキャッシュフローに基づき、3 年以上にわたって十分なキャッシュランウェイを有しています。

キャッシュランウェイの予測: SLNC.Fは、フリーキャッシュフローが毎年29.1 % の歴史的率で減少し続ける場合、 2.1年間十分なキャッシュランウェイを有しています。

Silence Therapeutics バランスシートの健全性

財務の健全性 基準チェック /66

主要情報

財務の健全性に関する最新情報

Silence Therapeutics Updates on AIM Delisting

Recent updates

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Silence Therapeutics plc Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(A)

Silence Therapeutics plc Announces Retirement of Alistair Gray from Board of Directors, Effective May 1, 2024

Silence Therapeutics plc, Annual General Meeting, May 17, 2024

Silence Therapeutics plc Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Silence Therapeutics plc Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(A)

Silence Therapeutics plc to Report Q4, 2023 Results on Mar 13, 2024

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Silence Therapeutics plc Announces Retirement of Giles Campion as Chief Medical Officer, Head of Research & Development and Member of Board

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Provides SLN360 and SLN124 Clinical Program Updates

Silence Therapeutics plc Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting

Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia

Silence Therapeutics plc Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera

Silence Therapeutics plc, Annual General Meeting, Jun 14, 2022

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting

Silence Therapeutics plc to Report Q4, 2021 Results on Mar 17, 2022

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)

Silence Therapeutics plc Presents Additional Positive Data from the SLN124 Healthy Volunteer Study

Silence Therapeutics Updates on AIM Delisting

Silence Therapeutics plc announced that it has received $40 million in funding from AstraZeneca PLC

Silence Therapeutics plc Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers

Silence Therapeutics plc to Report Fiscal Year 2020 Results on Mar 30, 2021

Silence Therapeutics plc & Mallinckrodt plc Initiate Work on 3Rd Target

Silence Therapeutics plc announced that it has received $45.499905 million in funding from a group of investors

Silence Therapeutics plc Initiates Dosing in Phase 1 Clinical Trial of Sln360 for Cardiovascular Disease Due to High Lipoprotein(A)

Silence Therapeutics Appoints Michael H. Davidson to Board of Directors

Silence Therapeutics Appoints Craig Tooman as CFO

Silence Therapeutics plc Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) At American Heart Association 2020

Silence Therapeutics plc Appoints Marie Wikström Lindholm as Senior Vice President, Molecular Design and Member of the Silence Executive Leadership Team

Silence Therapeutics plc Announces Rob Quinn, the Current CFO Will Leave the Company in January 2021

Silence Therapeutics Appoints Mark Rothera as Chief Executive Officer

Silence Therapeutics plc has completed a Follow-on Equity Offering in the amount of $311.826401 million.

Silence Therapeutics plc to Report First Half, 2020 Results on Sep 14, 2020

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

キャッシュ・ランウェイ分析

健全な企業の発掘

財務の健全性基準チェック /66